Usona Institute will begin its Phase 3 Clinical Trial investigating psilocybin for Major Depressive Disorder (MDD), the company announced today. According to a release, the uAspire trial will start with…

The U.S. Food and Drug Administration granted Breakthrough Therapy Designation for Usona Institute‘s psilocybin for the treatment of major depressive disorder (MDD), the organization announced today. According to a release, the designation bolsters Usona’s…